New Platelet Aggregation Inhibitors

• REFERENCES

• 1 Boneu B. on behalf of the study investigators. Clopidogrel dose-ranging phase II-study in patients with atherosclerotic disease. J Am Coll Cardiol 1996; 27: 132A-133A (abstract)
• 2 Herbert JM, Frehel D, Vallee E. et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-98.
• 3 Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Drugs Ther 1992; 6: 29-33.
• 4 Savage MP, Goldberg S, Bove AA. et al. for the M-HEART II Study Group. Effect of thromboxane A₂ blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995; 92: 3194-200.
• 5 Collen D, Masuda M, Lu HR. et al. Effect of ridogrel, a combined thromboxane A₂ synthase inhibitor/prostaglandin endoperoxide receptor antagonist, on the lysis of platelet rich coronary arterial thrombi with recombinant tissue-plasminogen activator in a canine model. Fibrinolysis 1992; 6: 7-15.
• 6 Hoet B, Arnout J, Van Geet C. et al. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma β-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemost 1990; 64: 87-90.
• 7 The RAPT Investigators.. Randomized trial of ridogrel, a combined thromboxane A₂ synthase inhibitor and thromboxane A₂/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The ridogrel versus aspirin trial (RAPT). Circulation 1994; 89: 588-95.
• 8 Gresele P, Deckmyn H, Arnout J. et al. Characterization of N,N’-bis(3-picolyl)-4-methoxyisophtalamide (picotamide) as a dual thromboxane synthase inhibitor/throm-boxane A₂ receptor antagonist in human platelets. Thromb Haemost 1989; 61: 479-84.
• 9 Plow EF, Ginsberg MH. Cellular adhesion: GP Ilb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1988; 9: 117-56.
• 10 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein Ilb-IIIa (integrin αllbβ3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267: 11300-6.
• 11 Peerlinck K, Delepeleire I, Goldberg M. et al. MK-383 – a selective, non-peptide platelet glycoprotein Ilb/IIIa receptor antagonist active in man. Circulation 1993; 88: 1512-7.
• 12 Collen D, Lu HR, Stassen JM. et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GP Ilb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994; 71: 95-102.
• 13 Kleiman NS, Ohman EM, Califf RM. et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-9.
• 14 Tcheng JE, Ellis SG, George BS. et al. Pharmacodynamics of chimeric glycoprotein lib/ Ilia integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty. Circulation 1994; 90: 1757-64.
• 15 The EPIC investigators.. Use of monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
• 16 Topol EJ, Califf RM, Weisman HF. et al. on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
• 17 Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein Ilb/IIIa inhibitors. Am Heart J 1995; 130: 666-72.
• 18 Lefkovits J, Ivanhoe RJ, Califf RM. et al. for the EPIC Investigators. Effects of platelet glycoprotein Ilb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77: 1045-51.
• 19 Simoons ML, den Boer MJ, van den Brand MJBM. et al. and the European Cooperative Study Group. Randomized trial of a GPIIb/ Ilia platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
• 20 Tcheng JE. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J 1995; 130: 673-9.
• 21 Lincoff AM, Tcheng JE, Bass TA. et al. A multicenter, randomized, double-blind pilot trial of a standard versus low-dose weight, adjusted heparin in patients treated with the platelet GPIIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization. J Am Coll Cardiol 1995; 25: 80A-81A (abstract)
• 22 Harrington RA, Kleiman NS, Kottke-Marchant K. et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein Ilb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-7.
• 23 Tcheng JE, Harrington RA, Kottke-Mar-chant K. et al. for the Impact Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein Ilb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995; 91: 2151-7.
• 24 Tcheng JE, Lincoff AM, Sigmon KN. et al. for the Impact II Investigators. Platelet glycoprotein Ilb/IIIa inhibition with integrelin during percutaneous coronary intervention:the IMPACT II trial. Circulation 1995; 2 Suppl 1: 1-543 abstract
• 25 Bergelson BA, Davidson CJ, Hafley G. et al. for the Impact II Investigators. Predictors of abrupt closure and consequences of emergency endpoints in the IMPACT II trial. J Am Coll Cardiol 1996; 27: 83A (abstract)
• 26 Barrett JS, Murphy MG, Peerlinck K. et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein Ilb/IIIa receptor antagonist in healthy men. Clin Pharmacol Ther 1994; 56: 377-88.
• 27 Lynch JJ, Cook JJ, Sitko GR. et al. Non-peptide glycoprotein Ilb/IIIA inhibitors. 5 Antithrombotic effects of MK-383. J Pharmacol Exp Ther 1995; 272: 20-32.
• 28 Kereiakes DJ, Kleiman NS, Ambrose J. et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet Ilb/IIIa blockade in high risk patients undergoing cornary angioplasty. J Am Coll Cardiol 1996; 27: 536-42.
• 29 Kottke-Marchant K, Simpfendorfer C, Lowrie M. et al. Sustained but variable inhibition of platelet aggregation with xem-lofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation 1995; 92 (Suppl. 01) 1-488 (abstract).
• 30 Simpfendorfer C, Kottke-Marchant K, Topol EJ. First experience with chronic platelet GPIIb/IIIa receptor blockade: a pilot study of xemlofiban, an orally active antagonist in unstable angina patients eligible for PTCA. J Am Coll Cardiol 1996; 27: 242A (abstract)
• 31 Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-84.
• 32 Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-6.
• 33 Choi ET, Engel L, Callow AD. et al. Inhibition of neointimal hyperplasia by blocking α_vβ₃ integrin with a small peptide antagonist G-pen GRGDSPCA. J Vase Surg 1994; 19: 125-34.